ストックスクリーナーアプリを入手
64.26
1.28%
0.81
アフターアワーズ：
64.26
前日終値:
$63.45
開ける：
$63.88
24時間の取引高:
1.24M
Relative Volume:
0.72
時価総額：
$13.13B
収益：
$2.75B
当期純損益:
$322.29M
株価収益率:
83.60
EPS:
0.7687
ネットキャッシュフロー:
$300.88M
1週間 パフォーマンス:
+1.32%
1か月 パフォーマンス:
-8.89%
6か月 パフォーマンス:
-15.95%
1年 パフォーマンス:
-27.32%
1日の値動き範囲:
$63.78
$64.46
1週間の範囲:
$61.15
$64.46
52週間の値動き範囲:
$61.15
$99.56
Biomarin Pharmaceutical Inc Stock (BMRN) Company Profile
名前
Biomarin Pharmaceutical Inc
セクター
電話
(415) 506-6700
住所
105 DIGITAL DRIVE, NOVATO, CA
BMRN を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
| BMRN | 64.26 | 13.13B | 2.75B | 322.29M | 300.88M | 0.7687 |
| VRTX | 450.97 | 116.14B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 738.00 | 81.10B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 605.92 | 36.23B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 244.89 | 31.59B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 113.13 | 27.12B | 3.30B | -501.07M | 1.03B | 11.54 |
Biomarin Pharmaceutical Inc Stock (BMRN) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-10-10 | 再開されました | Raymond James | Outperform |
| 2024-08-20 | アップグレード | Bernstein | Mkt Perform → Outperform |
| 2024-05-17 | ダウングレード | Robert W. Baird | Outperform → Neutral |
| 2024-05-14 | 開始されました | Evercore ISI | Outperform |
| 2023-11-15 | 開始されました | Wells Fargo | Overweight |
| 2023-10-23 | アップグレード | Bernstein | Underperform → Mkt Perform |
| 2023-09-28 | 開始されました | Raymond James | Mkt Perform |
| 2023-09-18 | 開始されました | UBS | Buy |
| 2023-07-27 | 開始されました | Scotiabank | Sector Perform |
| 2023-07-05 | アップグレード | BMO Capital Markets | Market Perform → Outperform |
| 2023-06-14 | 再開されました | Credit Suisse | Outperform |
| 2023-03-21 | 開始されました | Bernstein | Underperform |
| 2023-02-22 | ダウングレード | Oppenheimer | Outperform → Perform |
| 2023-02-21 | 開始されました | Citigroup | Neutral |
| 2023-01-30 | 開始されました | BMO Capital Markets | Market Perform |
| 2023-01-18 | 開始されました | Canaccord Genuity | Hold |
| 2022-10-31 | アップグレード | Oppenheimer | Perform → Outperform |
| 2022-07-13 | 開始されました | Cantor Fitzgerald | Overweight |
| 2022-06-13 | 再開されました | Wedbush | Neutral |
| 2022-04-25 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2021-11-22 | アップグレード | William Blair | Mkt Perform → Outperform |
| 2021-10-07 | 再開されました | Jefferies | Buy |
| 2021-09-09 | アップグレード | Stifel | Hold → Buy |
| 2021-06-04 | 再開されました | Robert W. Baird | Outperform |
| 2021-04-26 | 再開されました | Credit Suisse | Outperform |
| 2021-03-04 | 再開されました | Guggenheim | Buy |
| 2021-03-01 | アップグレード | Evercore ISI | In-line → Outperform |
| 2020-08-20 | ダウングレード | Citigroup | Buy → Neutral |
| 2020-08-20 | ダウングレード | William Blair | Outperform → Mkt Perform |
| 2020-08-19 | ダウングレード | Evercore ISI | Outperform → In-line |
| 2020-08-19 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
| 2020-08-19 | ダウングレード | Stifel | Buy → Hold |
| 2020-07-08 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2020-07-06 | 繰り返されました | Citigroup | Buy |
| 2020-01-28 | 開始されました | BMO Capital Markets | Market Perform |
| 2020-01-27 | 開始されました | BMO Capital Markets | Market Perform |
| 2020-01-24 | アップグレード | RBC Capital Mkts | Sector Perform → Outperform |
| 2019-11-27 | アップグレード | Barclays | Equal Weight → Overweight |
| 2019-11-12 | 開始されました | SunTrust | Buy |
| 2019-10-17 | 再開されました | BofA/Merrill | Buy |
| 2019-05-23 | 再開されました | Citigroup | Buy |
| 2019-04-09 | 再開されました | Raymond James | Outperform |
| 2019-01-02 | ダウングレード | Raymond James | Outperform → Mkt Perform |
| 2018-12-14 | 開始されました | Wolfe Research | Outperform |
| 2018-10-01 | 開始されました | Cantor Fitzgerald | Overweight |
| 2018-08-07 | 繰り返されました | Stifel | Buy |
| 2018-08-03 | 繰り返されました | Stifel | Buy |
すべてを表示
Biomarin Pharmaceutical Inc (BMRN) 最新ニュース
King Luther Capital Management Corp Makes New Investment in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) - MarketBeat
Connor Clark & Lunn Investment Management Ltd. Invests $8.17 Million in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) - MarketBeat
Can BioMarin Stock Live Up to Wall Street’s High Expectations? - sharewise
What is Zacks Research's Forecast for BMRN FY2024 Earnings? - MarketBeat
Can BioMarin Stock Live Up to Wall Street's High Expectations? - Benzinga
Why Is BioMarin Pharmaceutical Inc. (BMRN) Among the Worst Performing Biotech Stocks in 2024? - Yahoo Finance
Layoff Tracker: J&J, Merck Trimming Workforces in China - BioSpace
BioMarin: Challenges Mount, But Sale Rumors Make For A Risky 'Buy' Call (NASDAQ:BMRN) - Seeking Alpha
Here's Why BioMarin Pharmaceutical (BMRN) is a Strong Value Stock - Yahoo Finance
Zacks Research Brokers Raise Earnings Estimates for BMRN - MarketBeat
Primecap Management Co. CA Acquires 77,350 Shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) - MarketBeat
Phenylketonuria Market size is ~700 USD million in 2023, asserts DelveInsight | Pharma Giants: PTC Therapeutics, Homology Medicines, Synlogic, BioMarin Pharmaceuticals - The Globe and Mail
Here's Why BioMarin Pharmaceutical (BMRN) is a Strong Growth Stock - Yahoo Finance
EULAV Asset Management Grows Holdings in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) - MarketBeat
Wolfe Research Initiates Coverage of BioMarin Pharmaceutical (BMRN) with Outperform Recommendation - MSN
Howe & Rusling Inc. Acquires 24,971 Shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) - MarketBeat
BioMarin Pharmaceutical Inc. (BMRN): Among the Best Genomics Stocks to Buy Right Now - Insider Monkey
Implied Volatility Surging for BioMarin Pharmaceutical (BMRN) Stock Options - MSN
10 Biggest Biotechnology Companies - Investopedia
Sumitomo Mitsui Trust Group Inc. Has $32.06 Million Stock Position in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) - MarketBeat
BioMarin's VOXZOGO Shows Remarkable Height Gains in 452-Child Achondroplasia Study | BMRN Stock News - StockTitan
Comgest Global Investors S.A.S. Trims Position in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) - MarketBeat
Los Angeles Capital Management LLC Acquires New Holdings in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) - MarketBeat
BioMarin stock touches 52-week low at $65.23 amid challenges - Investing.com India
BioMarin Pharmaceutical (NASDAQ:BMRN) Hits New 1-Year Low on Insider Selling - MarketBeat
BioMarin Pharmaceutical (NASDAQ:BMRN) Now Covered by Analysts at Wolfe Research - MarketBeat
Biomarin pharmaceutical's CTO sells $350k in stock By Investing.com - Investing.com Nigeria
Biomarin pharmaceutical's CTO sells $350k in stock - Investing.com India
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Not Flying Under The Radar - Simply Wall St
WCM Investment Management LLC Has $1.20 Million Stock Position in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) - MarketBeat
abrdn Life Sciences Investors declares $0.50 dividend - MSN
Principal Financial Group Inc. Sells 191,421 Shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) - MarketBeat
How To Trade (BMRN) - Stock Traders Daily
National Pension Service Grows Stock Holdings in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) - MarketBeat
Here’s Why BioMarin Aristotle Large Cap Growth Strategy Divested From Pharmaceutical (BMRN) - Insider Monkey
Robeco Institutional Asset Management B.V. Buys 128,807 Shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) - MarketBeat
BioMarin to Participate in Three Upcoming Investor Conferences - StockTitan
BioMarin Pharmaceutical (NASDAQ:BMRN) Upgraded at Wedbush - MarketBeat
Why BioMarin Pharmaceutical (BMRN) is a Top Value Stock for the Long-Term - MSN
BioMarin Pharmaceutical Inc.: Enhancement of Enzyme Replacement Therapy (ERT) Portfolio - Smartkarma
CAMP4 Analyst Highlights Rare Disease Platform Potential - Benzinga
BioMarin's SWOT analysis: rare disease biotech stock faces growth challenges - Investing.com
AlphaCentric Advisors LLC Purchases 16,000 Shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) - MarketBeat
Ascendis Pharma Faces Challenges With Skytrofa And Yorvipath Pricing: Analysts Weigh In - MSN
Is BioMarin (BMRN) a Solid Growth Stock? 3 Reasons to Think "Yes" - Yahoo Finance
BioMarin (BMRN) Upgraded to Buy: Here's Why - Yahoo Finance UK
BMRN vs. INCY: Which Stock Is the Better Value Option? - Yahoo Finance
Why BioMarin Pharmaceutical (BMRN) is a Top Growth Stock for the Long-Term - Yahoo Finance
FY2024 Earnings Forecast for BMRN Issued By Leerink Partnrs - MarketBeat
F M Investments LLC Buys New Position in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) - MarketBeat
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Shares Sold by Rice Hall James & Associates LLC - MarketBeat
Biomarin Pharmaceutical Inc (BMRN) 財務データ
収益
当期純利益
現金流量
EPS
1.89%
2.08%
大文字化:
|
ボリューム (24 時間):